The FDA recorded supplement actions on two abbreviated new drug applications for generic antipsychotics: olanzapine from Sandoz on 1 October, and risperidone from Pharmazone on 22 September. An abbreviated application covers a generic copy of an established drug, and a supplement is a change to an existing approval, often to manufacturing, labelling or packaging.
The public record does not say what changed. Neither action is a new indication, a new formulation for clinicians to learn, or a safety communication.
For prescribers, nothing about how olanzapine or risperidone are used changes. The monitoring that matters is unchanged: weight, glucose and lipids for olanzapine, and prolactin-related effects and movement disorders for risperidone. Indian supply is regulated by CDSCO and is not affected by these US actions.
- No change to how olanzapine or risperidone are prescribed or monitored.
- These are administrative supplements to generic approvals, not new indications or safety warnings.
- Keep metabolic monitoring for olanzapine: weight, glucose and lipids.
- Keep watch for prolactin-related effects and extrapyramidal symptoms with risperidone.
Why it matters
Regulatory listings can look like news; knowing which ones are administrative saves a needless change of prescription.
Don't overread it
A supplement to a generic approval is not a new indication or a safety signal.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free